$33.03
4.42%
Downside
Day's Volatility :6.96%
Upside
2.65%
80.62%
Downside
52 Weeks Volatility :86.51%
Upside
30.39%
Period | Dyne Therapeutics, Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.76% | 5.1% | 0.0% |
6 Months | 24.92% | 4.9% | 0.0% |
1 Year | 186.72% | 16.6% | 0.0% |
3 Years | 102.76% | 13.2% | -22.3% |
Market Capitalization | 3.4B |
Book Value | $7.74 |
Earnings Per Share (EPS) | -3.58 |
PEG Ratio | 0.19 |
Wall Street Target Price | 53.22 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.45% |
Return On Equity TTM | -52.46% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -269.5M |
Diluted Eps TTM | -3.58 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.0 |
EPS Estimate Next Year | -3.28 |
EPS Estimate Current Quarter | -0.72 |
EPS Estimate Next Quarter | -0.73 |
What analysts predicted
Upside of 61.13%
Sell
Neutral
Buy
Dyne Therapeutics, Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dyne Therapeutics, Inc | -21.71% | 24.92% | 186.72% | 102.76% | 38.2% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dyne Therapeutics, Inc | NA | NA | 0.19 | -3.0 | -0.52 | -0.31 | NA | 7.74 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dyne Therapeutics, Inc | Buy | $3.4B | 38.2% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
FCPM III SERVICES BV
BlackRock Inc
RTW INVESTMENTS, LLC
RA Capital Management, LLC
FMR Inc
Vanguard Group Inc
Dyne Therapeutics, Inc’s price-to-earnings ratio stands at None
Read Moredyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.
Organization | Dyne Therapeutics, Inc |
Employees | 152 |
CEO | Ms. Susanna Gatti High M.B.A. |
Industry | Commercial Services |
Assetmark Financial Holdings Inc
$33.03
-1.84%
Fidelity Msci Health Care Etf
$33.03
-1.84%
Texas Capital Bancshares Inc.
$33.03
-1.84%
Primerica, Inc.
$33.03
-1.84%
Thor Industries Inc.
$33.03
-1.84%
Qifu Technology Inc
$33.03
-1.84%
Crinetics Pharmaceuticals Inc
$33.03
-1.84%
Hercules Capital Inc
$33.03
-1.84%
Janus Henderson Mortgage-backed Securities Etf
$33.03
-1.84%